Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis.

Mills E, Wilson K, Clarke M, Foster B, Walker S, Rachlis B, DeGroot N, Montori VM, Gold W, Phillips E, Myers S, Gallicano K.

Eur J Clin Pharmacol. 2005 Mar;61(1):1-7. Epub 2005 Jan 22.

PMID:
15666173
2.

Coadministration of milk thistle and indinavir in healthy subjects.

DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R, Morse G.

Pharmacotherapy. 2003 Jul;23(7):866-70.

PMID:
12885100
3.

Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers.

Piscitelli SC, Formentini E, Burstein AH, Alfaro R, Jagannatha S, Falloon J.

Pharmacotherapy. 2002 May;22(5):551-6.

PMID:
12013352
4.

Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers.

Slain D, Amsden JR, Khakoo RA, Fisher MA, Lalka D, Hobbs GR.

Pharmacotherapy. 2005 Feb;25(2):165-70.

PMID:
15767232
5.

Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans.

Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y, Cheboyina S.

Drug Metab Dispos. 2006 Jan;34(1):69-74. Epub 2005 Oct 12.

6.

Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.

Ofotokun I, Acosta EP, Lennox JL, Pan Y, Easley KA.

Pharmacotherapy. 2008 Jan;28(1):74-81.

7.

Toxicity. Milk thistle and indinavir.

[No authors listed]

TreatmentUpdate. 2002 Sep-Oct;14(7):4-5. No abstract available.

PMID:
12400499
8.

The effect of azithromycin on the pharmacokinetics of indinavir.

Foulds G, LaBoy-Goral L, Wei GC, Apseloff G.

J Clin Pharmacol. 1999 Aug;39(8):842-6.

PMID:
10434237
9.

Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.

Jann MW, Spratlin V, Momary K, Zhang H, Turner D, Penzak SR, Wright A, VanDenBerg C.

Eur J Clin Pharmacol. 2012 May;68(5):715-21. doi: 10.1007/s00228-011-1180-7. Epub 2011 Dec 16.

PMID:
22173281
10.

The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.

Aarnoutse RE, Grintjes KJ, Telgt DS, Stek M Jr, Hugen PW, Reiss P, Koopmans PP, Hekster YA, Burger DM.

Clin Pharmacol Ther. 2002 Jan;71(1):57-67.

PMID:
11823758
11.

Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients.

Cruciani M, Gatti G, Vaccher E, Di Gennaro G, Cinelli R, Bassetti M, Tirelli U, Bassetti D.

J Antimicrob Chemother. 2005 Apr;55(4):546-9. Epub 2005 Feb 22.

PMID:
15728147
12.

Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin.

Hamzeh FM, Benson C, Gerber J, Currier J, McCrea J, Deutsch P, Ruan P, Wu H, Lee J, Flexner C; AIDS Clinical Trials Group 365 Study Team.

Clin Pharmacol Ther. 2003 Mar;73(3):159-69.

PMID:
12621381
13.

Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers.

Ferry JJ, Herman BD, Carel BJ, Carlson GF, Batts DH.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jul 1;18(3):252-9.

PMID:
9665503
14.

Interaction of sildenafil and indinavir when co-administered to HIV-positive patients.

Merry C, Barry MG, Ryan M, Tjia JF, Hennessy M, Eagling VA, Mulcahy F, Back DJ.

AIDS. 1999 Oct 22;13(15):F101-7.

PMID:
10546851
15.

No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers.

Purkins L, Wood N, Kleinermans D, Love ER.

Br J Clin Pharmacol. 2003 Dec;56 Suppl 1:62-8.

16.

The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin.

Boruchoff SE, Sturgill MG, Grasing KW, Seibold JR, McCrea J, Winchell GA, Kusma SE, Deutsch PJ.

Clin Pharmacol Ther. 2000 Apr;67(4):351-9.

PMID:
10801243
17.

Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir.

Tappouni HL, Rublein JC, Donovan BJ, Hollowell SB, Tien HC, Min SS, Theodore D, Rezk NL, Smith PC, Tallman MN, Raasch RH, Kashuba AD.

Am J Health Syst Pharm. 2008 Mar 1;65(5):422-8. doi: 10.2146/ajhp070226.

18.

Pharmacokinetics of indinavir in Koreans and Caucasians.

Choi JY, Chang KH, Park YS, Cho CH, Shin SY, Song YG, Kim JM.

Scand J Infect Dis. 2004;36(4):307-9.

PMID:
15198191
19.

Milk thistle for the treatment of liver disease: a systematic review and meta-analysis.

Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA.

Am J Med. 2002 Oct 15;113(6):506-15. Review.

PMID:
12427501
20.

Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.

Burger DM, van Rossum AM, Hugen PW, Suur MH, Hartwig NG, Geelen SP, Scherpbier HJ, Hoetelmans RM, Vulto AG, de Groot R; Dutch Study Group for Children with HIV-1 Infection.

Antimicrob Agents Chemother. 2001 Mar;45(3):701-5.

Supplemental Content

Support Center